Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

MNG1164

35e098dc-284a-56de-81e3-e2764c299c31

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • KRAS_SIGNALING_DN+0.376
  • SPERMATOGENESIS+0.318
  • PANCREAS_BETA_CELLS+0.300
  • HEDGEHOG_SIGNALING+0.101
  • ESTROGEN_RESPONSE_LATE+0.058
  • COAGULATION-0.023
  • KRAS_SIGNALING_UP-0.027
  • MYOGENESIS-0.040
  • APICAL_JUNCTION-0.045
  • ESTROGEN_RESPONSE_EARLY-0.063

Top 10 suppressed

  • OXIDATIVE_PHOSPHORYLATION-0.595
  • PROTEIN_SECRETION-0.578
  • MYC_TARGETS_V1-0.562
  • UNFOLDED_PROTEIN_RESPONSE-0.476
  • ADIPOGENESIS-0.474
  • TGF_BETA_SIGNALING-0.473
  • ANDROGEN_RESPONSE-0.472
  • FATTY_ACID_METABOLISM-0.471
  • MTORC1_SIGNALING-0.468
  • DNA_REPAIR-0.448

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR1366141
brain-umap@2
GTEX0.967
2MNG598
mng-umap@100
0.963
3MNG555
mng-umap@100
0.962
4MNG1003
mng-umap@100
0.959
5MNG1131
mng-umap@100
0.959
6MNG597
mng-umap@100
0.953
7msclc569389_S35.txt
lung-landscapes@6
cohortMD10.952
8SRR1323130
brain-umap@2
GTEX0.952
908e3d239-3d8a-4eee-9e08-ac2bcb3f2619
melanoma-umap@29
0.951
10SRR12696761
melanoma-umap@29
0.947

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 5 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
KRAS_SIGNALING_DN0.376Remibrutinib— uncovered
SPERMATOGENESIS0.318Inavolisib— uncovered
PANCREAS_BETA_CELLS0.300Cobimetinib— uncovered
HEDGEHOG_SIGNALING0.101Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.058Idelalisib— uncovered